All In Biotech

Drug Trial Radar · NCT05051930

A Clinical Trial of TQC3721 Suspension for Inhalation

Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Primary Efficacy of TQC3721 Suspension for Inhalation

Last checked: Nov 20, 2026Latest source record: Oct 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 114 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

114

Planned (sponsor's estimate)

Start

Oct 18, 2021

Primary completion

Oct 31, 2022

Study completion Dec 31, 2022

Sponsor

Sponsor type
Industry
First posted
Sep 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability and pharmacokinetic characteristics of TQC3721 suspension for inhalation in single/multiple administration(s) in healthy subjects; to evaluate the safety,tolerability and efficacy TQC3721 suspension for inhalation in multiple administrations in patients with Chronic Obstructive Pulmonary Disease(COPD)and asthma.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • TQC3721 suspension for inhalationDrug

    Participants will receive 0.2 mg/1.0 mg/3.0 mg/6.0 mg/12.0 mg/24.0 mg single dose of TQC3721 suspension for inhalation.

  • TQC3721 suspension placebo for inhalationDrug

    Participants will receive 0mg single dose of TQC3721 suspension placebo for inhalation .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse eventsTime frame: From the enrollment of the subjects to 72 hours after the last administration
  2. Incidence of adverse eventsTime frame: From the enrollment of the subjects to 72 hours after the last administration
  3. Number of adverse events related to the study drugTime frame: From the enrollment of the subjects to 72 hours after the last administration
  4. Incidence of adverse events associated with the study drugTime frame: From the enrollment of the subjects to 72 hours after the last administration
  5. Area Under The Curve(AUC)Time frame: Within 60 minutes before each administration, to 72 hours after administration
  6. Plasma drug peak concentration(Cmax )Time frame: Within 60 minutes before each administration, to 72 hours after administration
  7. Time to peak(Tmax)Time frame: Within 60 minutes before each administration, to 72 hours after administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.